
Takeda Pharmaceutical Co Ltd
TSE:4502

Intrinsic Value
Takeda Pharmaceutical Co., Ltd. engages in the research and development, manufacture, import and export sale, and marketing of pharmaceutical drugs. [ Read More ]
The intrinsic value of one
Takeda Pharmaceutical Co Ltd
stock under the Base Case scenario is
5 469.04
JPY.
Compared to the current market price of 4 171 JPY,
Takeda Pharmaceutical Co Ltd
is
Undervalued by 24%.

Valuation History
Takeda Pharmaceutical Co Ltd

Intrinsic Value History...
Our system is conducting in-depth analyses to map out the stock's valuation journey. Thank you for waiting.
Fundamental Analysis
2024-Q2 Earnings Call
NEW
Artifical Intelligence Analysis
Takeda Pharmaceutical's Q2 earnings revealed a mixed picture: a 2.1 trillion JPY revenue with a full-year forecast increase, countered by a profit forecast reduction due to noncore items impacting the quarter. The core operating profit margin target remains on track at 28%, aiming for a full-year target of 1,015 billion JPY. Takeda anticipates a growth return between 2024-2025, although the timeline may be tight due to potential fluctuations. The company's recent FDA approval for ENTYVIO's subcutaneous administration, a dengue vaccine recommendation from WHO, and robust pipeline milestones bolster their positive outlook. However, margin pressures from product mix changes and competition in the ulcerative colitis treatment market are important considerations for investors.
Balance Sheet Decomposition
Takeda Pharmaceutical Co Ltd
Current Assets | 2.5T |
Cash & Short-Term Investments | 334B |
Receivables | 788B |
Other Current Assets | 1.3T |
Non-Current Assets | 12.4T |
Long-Term Investments | 416B |
PP&E | 1.9T |
Intangibles | 9.7T |
Other Non-Current Assets | 396B |
Current Liabilities | 2.4T |
Accounts Payable | 421B |
Other Current Liabilities | 1.9T |
Non-Current Liabilities | 5.4T |
Long-Term Debt | 4.4T |
Other Non-Current Liabilities | 1T |
Profitability Score
Profitability Due Diligence
Takeda Pharmaceutical Co Ltd's profitability score is 55/100. The higher the profitability score, the more profitable the company is.

Score
Takeda Pharmaceutical Co Ltd's profitability score is 55/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
Takeda Pharmaceutical Co Ltd's solvency score is 36/100. The higher the solvency score, the more solvent the company is.

Score
Takeda Pharmaceutical Co Ltd's solvency score is 36/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
Takeda Pharmaceutical Co Ltd
According to Wall Street analysts, the average 1-year price target for
Takeda Pharmaceutical Co Ltd
is 4 854.63 JPY
with a low forecast of 4 141 JPY and a high forecast of 6 090 JPY.
Shareholder Return
Price
Takeda Pharmaceutical Co Ltd
Average Annual Return | -2.37% |
Standard Deviation of Annual Returns | 14.98% |
Max Drawdown | -37% |
Market Capitalization | 6.5T JPY |
Shares Outstanding | 1 571 786 000 |
Percentage of Shares Shorted |
N/A
|
Company Profile


Country
Industry
Market Cap
Dividend Yield
Description
Takeda Pharmaceutical Co., Ltd. engages in the research and development, manufacture, import and export sale, and marketing of pharmaceutical drugs. The company is headquartered in Chuo-Ku, Tokyo-To and currently employs 47,347 full-time employees. The firm is engaged in the research, development, manufacture and sale of pharmaceutical products, General medical products, quasi drugs and healthcare products in Japan and overseas. The firm's research and development functions are concentrated in four areas of oncology (cancer), digestive system diseases, rare diseases and neurology (neuropsychiatric diseases), as well as two business units of plasma fractionation products and vaccines. The firm is engaged in the improvement of pipelines at research and development centers located mainly in Japan and the United States.
Contact
IPO
Employees
Officers
The intrinsic value of one
Takeda Pharmaceutical Co Ltd
stock under the Base Case scenario is
5 469.04
JPY.
Compared to the current market price of 4 171 JPY,
Takeda Pharmaceutical Co Ltd
is
Undervalued by 24%.